AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.
If approved, it would be the first antibody protection of its kind in Canada.
The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.
Get weekly health news
AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.
- ‘Maddening’: Family of Winnipeg woman who died after lengthy hospital wait calls for change
- Saskatchewan health-care workers vote 99% in favour of job action: CUPE
- Patients face challenges when seeking medical care not offered in Nova Scotia: audit
- Nova Scotia aims to reduce mammogram wait times, enhance women’s health care
-
![]()
Reasearchers watch closely as the latest strain of the flu virus makes its way to Canada for the upcoming respiratory virus season -
![]()
Nova Scotia unveils initatives to improve women’s health care -
![]()
EPA shortage leaves N.S. student attending school only part time -
![]()
Endometrial cancer awareness campaign kicks off, doctors say more education needed
The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.
Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.
Comments
Want to discuss? Please read our Commenting Policy first.